Research Analysts Offer Predictions for PLYX Q2 Earnings

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) – HC Wainwright issued their Q2 2026 earnings estimates for shares of Polaryx Therapeutics in a research report issued to clients and investors on Thursday, July 9th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. HC Wainwright also issued estimates for Polaryx Therapeutics’ Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.28) EPS.

PLYX has been the subject of several other research reports. Wall Street Zen cut Polaryx Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings raised Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Wednesday, July 1st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.50.

Polaryx Therapeutics Stock Performance

PLYX stock opened at $2.33 on Monday. Polaryx Therapeutics has a one year low of $2.01 and a one year high of $48.91. The stock has a market cap of $109.58 million and a price-to-earnings ratio of -46.60. The firm’s 50 day moving average price is $2.86.

Polaryx Therapeutics (NASDAQ:PLYX) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter.

Insider Transactions at Polaryx Therapeutics

In other news, CEO Alex Keun Mo Yang bought 88,453 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were bought at an average price of $4.07 per share, with a total value of $360,003.71. Following the completion of the transaction, the chief executive officer directly owned 24,233,249 shares in the company, valued at $98,629,323.43. This trade represents a 0.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Key Headlines Impacting Polaryx Therapeutics

Here are the key news stories impacting Polaryx Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Polaryx Therapeutics and kept its $7.00 price objective, signaling continued analyst confidence in the company’s outlook.
• Neutral Sentiment: The firm released earnings estimates for Q2 2026 through FY2027, projecting ongoing losses, including FY2026 EPS of ($0.22) and FY2027 EPS of ($0.28). The forecast reflects expected development-stage losses rather than a near-term profitability surprise.
• Neutral Sentiment: Quarterly estimates were also updated for Q2 2026 ($0.05), Q3 2026 ($0.06), Q4 2026 ($0.06), and multiple 2027 quarters at ($0.07) per share, but there was no new clinical or regulatory catalyst in the report. Polaryx Therapeutics stock page

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.